1. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial 
Michael W. Konstan, Patrick A. Flume, Matthias Kappler, Raphaël Chiron, Mark Higgins, Florian Brockhaus, Jie Zhang, Gerhild Angyalosi, Ellie He, David E. Geller 
Journal of Cystic Fibrosis 
Volume 10, Issue 1, Pages (January 2011)
DOI: /j.jcf
Copyright © 2010 European Cystic Fibrosis Society. Terms and Conditions

2. Fig. 1 Study design (A) and disposition (B).
Journal of Cystic Fibrosis  , 54-61DOI: ( /j.jcf )
Copyright © 2010 European Cystic Fibrosis Society. Terms and Conditions

3. Fig. 2
Overall efficacy: A) relative change in FEV1% predicted from baseline over three cycles (efficacy population); and B) change from baseline in Pseudomonas aeruginosa sputum density (efficacy population).
Journal of Cystic Fibrosis  , 54-61DOI: ( /j.jcf )
Copyright © 2010 European Cystic Fibrosis Society. Terms and Conditions